Phase I/II study protocol to assess safety and efficacy of adoptive cell therapy with anti-PD-1 plus low-dose pegylated-interferon-alpha in patients with metastatic melanoma refractory to standard of care treatments: the ACTME trial

• Published in: BMJ open Vol. 10; no. 11; p. e044036
• Main Authors: van der Kooij, Monique K, Verdegaal, Els M E, Visser, Marten, de Bruin, Linda, van der Minne, Caroline E, Meij, Pauline M, Roozen, Inge C F M, Jonker, Mare A, van den Bosch, Shelley, Liefers, Gerrit-Jan, Speetjens, Frank M, van der Burg, Sjoerd H, Kapiteijn, Ellen
• Format: Journal Article
• Language: English
• Published: England BMJ Publishing Group LTD 24.11.2020; BMJ Publishing Group
• Series: Protocol
• Subjects: Cell- and Tissue-Based Therapy; Chemotherapy; Clinical Trials, Phase I as Topic; Clinical Trials, Phase III as Topic; Cytotoxicity; Hepatitis; Humans; Immunotherapy; Interferon-alpha; Lymphocytes; Melanoma; Melanoma - drug therapy; Metastasis; Netherlands; Oncology; Polyethylene Glycols; Proteins; Skin cancer; Standard of Care; T cell receptors; Viruses; Netherlands; dermatological tumours; immunology; oncology
• ISSN: 2044-6055; 2044-6055
• DOI: 10.1136/bmjopen-2020-044036

IntroductionTreatment with anti-PD-1 immunotherapy does not lead to long-lasting clinical responses in approximately 60% of patients with metastatic melanoma. These refractory patients, however, can still respond to treatment with tumour infiltrating lymphocytes (TIL) and interferon-alpha (IFNa). A combination of TIL, pegylated-interferon-alpha (PEG-IFNa) and anti-PD-1 is expected to provide a safe, feasible and effective therapy for patients with metastatic melanoma, who are refractory to standard of care treatment options.Methods and analysisPatients are treated in two phases. In phase I, the safety of the combination TIL and anti-PD-1 is assessed (cohort 1) according to CTCAE 4.03 criteria. Subsequently, the safety of cotreatment with PEG-IFNa is tested in cohort 2. The efficacy will be evaluated in the second phase of the trial. Efficacy is evaluated according to RECIST 1.1 and immune-related response criteria. Clinical and immunological parameters will be evaluated for their relation with clinical responsiveness.Ethics and disseminationEthical approval of the trial was obtained from the Central Committee on Research Involving Human Subjects in the Netherlands. The trial results will be shared with the scientific community at (inter)national conferences and by publication in a peer-reviewed journal.Trial registration numberNCT03638375; Pre-results.